The Mass Spectrometry Core will provide the powerful tools of modern mass spectrometry to DPPGinvestigators. Quantification of both lipids and oxidized amino acids by GC/MS remains a mainstay of theCore. The Core will also permit structural identification and quantitation of high density lipoprotein (HDL)-related biomolecules, including apolipoprotein A-l and serum amyloid protein. Over the past two years, Corepersonnel have also become proficient in 2-dimensional liquid chromatography-electrospray ionization-MS/MS analysis (shotgun proteomics) of complex biological mixtures of proteins, and we anticipate that allinvestigators will take advantage of this capability in the next funding period.In addition to providing instrumental capabilities, Mass Spectrometry Core staff will provide consultation andcollaboration on the application of mass spectrometry to the DPPG research program, and this will includedevelopment of new analytical methods targeted at achieving research objectives of DPPG investigators.The Mass Spectrometry Core will optimize the efficiency and cost-effectiveness through which theseservices are provided to DPPG investigators by providing a central laboratory. This avoids the need forindividual DPPG investigators to maintain the required instrumentation in their own laboratories and avoidsthe high cost of commercial mass spectrometric services. By centralizing and standardizing procedures, theMass Spectrometry Core will provide a common set of analytical tools that will lead to a unifiedunderstanding of molecular mechanisms involved in physiologic and pathophysiologic processes of diabeticvascular disease.
Showing the most recent 10 out of 136 publications
